9th EUROPEAN SCHOOL OF DERMATO-ONCOLOGY UPDATE ON CUTANEOUS ONCOLOGY (ESDO)
JANUARY 15th-16th, 2021
VIRTUAL
OPDIVO® as monotherapy is indicated for the adjuvant treatment of adults with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.

The only therapy indicated in the adjuvant setting for all patients with stage III and stage IV NED melanoma#, 1,3–6


© 2020 Bristol-Myers Squibb Company. All rights reserved. OPDIVO®, YERVOY® and the related logos are trademarks of Bristol-Myers Squibb Company.
OPDIVO® + YERVOY® is the 1L treatment option with > 50% of patients alive at 5 years\textsuperscript{1,2}

Choose OPDIVO® + YERVOY® for the chance of durable survival\textsuperscript{1,2}

OPDIVO® as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. Relative to nivolumab monotherapy, an increase in progression-free survival (PFS) and overall survival (OS) for the combination of nivolumab with ipilimumab is established only in patients with low tumour PD-L1 expression.


This material has been produced to ensure compliance with the EFPIA and local German regulations. The indications in this material are listed according to the European Commission licensing. Prescribing information may vary depending on local approval in each country or region. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics (SPC).

©2020 Bristol-Myers Squibb Company. All rights reserved. OPDIVO®, YERVOY® and the related logos are trademarks of Bristol-Myers Squibb Company.

bms.com
European Association of Dermato-Oncology (EADO)

The EADO is a non-profit organization funded in 1999 to promote, coordinate and improve clinical and laboratory research activities in the field of skin cancer including primary and secondary prevention, early detection, clinical diagnosis and clinical and experimental research. EADO has organized many successful meetings and the upcoming ones are visible on the website (www.eado.org).

The EADO initiates for the ninth time a course dedicated to fundamentals in skin cancer targeted to specialists and residents in the final phase of their resident program. They will benefit a comprehensive and updated course to improve their decision-making process for the management of all types and stages of skin cancer, from diagnosis, primary treatment and adjuvant treatment, to the management of locoregional disease and distant metastatic disease.

Target Audience

This 2-day educational course targets doctors who are actively involved in the treatment of skin cancer. Dermatologists or other specialists who have completed specialist training, or residents in the final year of their training program, are likely to gain the most from this course.

Educational Objectives

The principal aim of the course is to provide a comprehensive and detailed understanding of the decision-making process for the management of all types and stages of skin cancer. This will include diagnosis and primary treatment, management of locoregional disease and distant metastatic disease, and adjuvant treatment. This is particularly relevant given the rapid progress in our understanding of melanoma and non-melanoma skin cancer, and the development of new treatments. In particular delegates will acquire the following knowledge:

1. Strategies for diagnosis of melanoma, Merkel cell and non-melanoma skin cancer including dermoscopy and confocal laser microscopy.
2. The indications, risks and benefits and strategies for mole screening.
3. Diagnosis of skin cancer: how to break bad news.
5. The present AJCC staging systems and how to stage melanoma, Merkel cell and cutaneous squamous cell carcinoma, and other non-melanoma skin cancers.
6. The value of imaging and biomarkers for the detection of metastases and disease staging.
8. New systemic treatments for stage IV melanoma: targeted agents and immunotherapeutics.
10. New systemic treatments for advanced Merkel cell and squamous cell carcinoma.
11. The characteristics of mucosal and uveal melanomas and their treatment options.
12. Options for topical treatment of epithelial skin cancers.
13. The current classification of cutaneous lymphoma, staging and treatment options for different subtypes of cutaneous lymphoma.
15. The indications and strategies for supportive treatments including best supportive care.

Course Organization

The course consists of plenary sessions and interactive outbreak sessions. Plenary sessions will comprise clear structured and up-to-date presentations followed by audience discussion. Voting devices will be used to respond to multiple choice questions. These questions may precede the presentation of the structured knowledge or may be presented at the end in order to test the level of knowledge the audience has gained.

The main part of the course consists of 6 interactive sessions. Every participant takes part in each of these sessions which mainly comprise case-based discussion. These will be used to illustrate treatment pathways, how risk and benefit are assessed, and how management decisions are made.

We look forward to welcoming you in January 2021!

Claus Garbe, MD  
Axel Hauschild, MD  
David Moreno-Ramirez, MD  
Iris Zalaudek, Trieste, MD  

Course Directors
Program Overview

Friday January 15th, 2021

Welcome Session

PLENARY SESSION 1:
C. Garbe
A. M. Forsea
J. J. Grob
I. Zalaudek
T. Dirschka

Break

COURSE A
Franz Trautinger

COURSE B
David Moreno-Ramirez

Saturday January 16th, 2021

Non-Melanoma Skin Cancer Day

PLENARY SESSION 4:
I. Zalaudek
A. Lallas
J. Malvehy
H. Kittler

Break

COURSE D
Jessica Hassel

COURSE E
Claus Garbe
# Program

## Friday, January 15th, 2021

### Non-Melanoma Skin Cancer Day

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:45-09:00</td>
<td><strong>Welcome and course introduction</strong>&lt;br/&gt;Claus Garbe, Tuebingen, Germany</td>
<td></td>
</tr>
<tr>
<td>09:00-09:20</td>
<td><strong>PLENARY SESSION 1: NMSC: What’s new?</strong>&lt;br/&gt;Chairpersons: Jean Jacques Grob and Ana-Maria Forsea</td>
<td></td>
</tr>
<tr>
<td>09:00-09:20</td>
<td><strong>LECTURE 1: Epidemiology</strong>&lt;br/&gt;Claus Garbe, Tuebingen, Germany</td>
<td></td>
</tr>
<tr>
<td>09:20-09:40</td>
<td><strong>LECTURE 2: Classification of cutaneous squamous cell carcinoma</strong>&lt;br/&gt;Ana-Maria Forsea, Bucharest, Romania</td>
<td></td>
</tr>
<tr>
<td>09:40-10:00</td>
<td><strong>LECTURE 3: Classification of advanced basal cell carcinoma</strong>&lt;br/&gt;Jean Jacques Grob, Marseille, France</td>
<td></td>
</tr>
<tr>
<td>10:00-10:20</td>
<td><strong>LECTURE 4: Locally advanced NMSC from a patient’s perspective</strong>&lt;br/&gt;Iris Zalaudek, Trieste, Italy</td>
<td></td>
</tr>
<tr>
<td>10:20-10:40</td>
<td><strong>LECTURE 5: What is new for actinic keratosis?</strong>&lt;br/&gt;Thomas Dirschka, Wuppertal, Germany</td>
<td></td>
</tr>
<tr>
<td>10:40-11:00</td>
<td><strong>Discussion</strong></td>
<td></td>
</tr>
<tr>
<td>11:00-11:15</td>
<td><strong>Break</strong></td>
<td></td>
</tr>
<tr>
<td>11:15-12:15</td>
<td><strong>COURSE A: Treatment of cutaneous lymphomas: Guidelines and more</strong>&lt;br/&gt;Franz Trautinger, St. Poelten, Austria</td>
<td></td>
</tr>
<tr>
<td>12:15-12:30</td>
<td><strong>Break</strong></td>
<td></td>
</tr>
<tr>
<td>12:30-13:30</td>
<td><strong>COURSE B: Surgical pearls in the treatment of NMSC</strong>&lt;br/&gt;David Moreno-Ramirez, Seville, Spain</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session/Activity</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>13:30-13:45</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>13:45-14:45</td>
<td><strong>COURSE C:</strong> Adjuvant, neoadjuvant and palliative immunotherapies for NMSC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Axel Hauschild, Kiel, Germany</td>
<td></td>
</tr>
<tr>
<td>14:45-15:00</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>14:45-15:00</td>
<td><strong>PLENARY SESSION 2:</strong> Guideline-based diagnosis and treatment of NMSC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairpersons: Ketty Peris and Ulrike Leiter</td>
<td></td>
</tr>
<tr>
<td>15:00-15:20</td>
<td><strong>LECTURE 6:</strong> Basal cell carcinoma</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ketty Peris, Rome, Italy</td>
<td></td>
</tr>
<tr>
<td>15:20-15:40</td>
<td><strong>LECTURE 7:</strong> Squamous cell carcinoma</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ulrike Leiter, Tuebingen, Germany</td>
<td></td>
</tr>
<tr>
<td>15:40-16:00</td>
<td><strong>LECTURE 8:</strong> Merkel cell carcinoma</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Celeste Lebbé, Paris, France</td>
<td></td>
</tr>
<tr>
<td>16:00-16:20</td>
<td><strong>LECTURE 9:</strong> Dermatofibrosarcoma protuberans</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Roland Kaufmann, Frankfurt, Germany</td>
<td></td>
</tr>
<tr>
<td>16:20-16:40</td>
<td><strong>Discussion</strong></td>
<td></td>
</tr>
<tr>
<td>16:40-17:00</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>17:00-18:00</td>
<td><strong>PLENARY SESSION 3:</strong> Difficult to treat non-melanoma skin cancers</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Interactive case discussion</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Presenter: Petr Arenberger, Veronique del Marmol, Judit Oláh</td>
<td></td>
</tr>
</tbody>
</table>
# Program

## Saturday, January 16th, 2021

### Melanoma Day

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Description</th>
<th>Speaker/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00-09:20</td>
<td>LECTURE 10: Dermoscopy of pigmented lesions</td>
<td>Iris Zalaudek, Trieste, Italy</td>
</tr>
<tr>
<td>09:20-09:40</td>
<td>LECTURE 11: Dermoscopy of non-pigmented lesions</td>
<td>Aimilios Lallas, Thessaloniki, Greece</td>
</tr>
<tr>
<td>09:40-10:00</td>
<td>LECTURE 12: Skin cancer apps: ready for prime time?</td>
<td>Josep Malvehy, Barcelona, Spain</td>
</tr>
<tr>
<td>10:00-10:20</td>
<td>LECTURE 13: New studies on artificial intelligence</td>
<td>Harald Kittler, Vienna, Austria</td>
</tr>
<tr>
<td>10:20-10:40</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>10:40-11:00</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>11:00-12:00</td>
<td>COURSE D: Management of adverse events of ICI and targeted therapies</td>
<td>Jessica Hassel, Heidelberg, Germany</td>
</tr>
<tr>
<td>12:00-12:15</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session and Details</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
</tbody>
</table>
**Claus Garbe, Tuebingen, Germany** |
| 13:15–13:30  | Break                                                                                                                                              |
| 13:30–14:30  | COURSE F: **Targeted therapies, immunotherapies and combinations for advanced metastatic melanomas**  
**Reinhard Dummer, Zurich, Switzerland** |
| 14:30–14:45  | Break                                                                                                                                              |
| 14:45–15:15  | PLENARY SESSION 5: **Perspectives in metastatic melanoma**  
**Chairpersons: Roland Kaufmann and Iris Zalaudek** |
| 15:15–15:45  | LECTURE 14: **Neoadjuvant melanoma treatment: replacing surgery soon?**  
**Axel Hauschild, Kiel, Germany** |
| 15:45–16:00  | Break                                                                                                                                              |
| 16:00–17:00  | PLENARY SESSION 6: **Difficult to treat melanomas**  
**Interactive case discussion**  
**Presenter: Lidija Kandolf-Sekulovic, Celeste Lebbé, Jessica Hassel** |
Invited Course Faculty

A

Petr Arenberger, MD
Professor of Dermatology, Director
Department of Dermatology
Charles University
3rd School of Medicine
Srobarova 50
Prague, Czech Republic
Email: avemedica@email.cz

F

Ana-Maria Forsea, MD
Associate Professor for Dermatology
Department of Dermatology
Carol Davila University of Medicine and Pharmacy Bucharest
Bulevardul Eroii Sanitari 8
Bucharest, Romania
Email: aforsea@yahoo.com

D

Veronique Del Marmol, MD
Department of Clinical Chemistry
Erasme Hospital – ULB
Route de Lennik 808
1070 Brussels, Belgium

Thomas Dirschka, MD
CentroDerm
Private practice
Heinz-Fangmann-Str. 57
Wuppertal, Germany
Email: info@centroderm.de

Reinhard Dummer, MD
Department of Dermatology
University of Zurich
Hospital
Gloriastrasse 31
Zurich, Switzerland
Email: reinhard.dummer@usz.ch

G

Claus Garbe, MD
Professor of Dermatology
Department of Dermatology
Eberhard Karls University
Liebermeister Str. 25
Tuebingen, Germany
Email: claus.garbe@med.uni-tuebingen.de

Jean Jacques Grob, MD
Professor of Dermatology
Service de Dermatology and Cancer Research
Hôpital de la Timone
264 Rue St. Pierre
Marseille, France
Email: jean-jacques.grob@ap-hm.fr
**H**

*Jessica Hassel, MD*
Department of Dermatology, University Hospital Heidelberg and Nationales Centrum für Tumorerkrankungen (NCT)
Im Neuenheimer Feld 460
Heidelberg, Germany
Email: jessica.hassel@med.uniheidelberg.de

*Axel Hauschild, MD*
Professor of Dermatology
Department of Dermatology
University of Kiel
Rosalind-Franklin-Str. 7
Kiel, Germany
Email: ahauschild@dermatology.uni-kiel.de

*Christoph Höller, MD*
Professor of Dermatology
Department of Dermatology
Medical University of Vienna
Waehringer Guertel 18-20
Vienna, Austria
Email: christoph.hoeller@meduniwien.ac.at

**Roland Kaufmann, MD**
Professor of Dermatology, Director
Department of Dermatology
Clinical Center J. W. Goethe University
Theodor-Stern-Kai 7
Frankfurt/Main, Germany
Email: kaufmann@em.uni-frankfurt.de

*Harald Kittler, MD*
Department of Dermatology
Medical University of Vienna
Waehringer Guertel 18-20
Vienna, Austria
Email: harald.kittler@meduniwien.ac.at

**L**

*Aimilos Lallas, MD*
Aristotle University of Thessaloiki
Department of Dermatology
Thessaloniki, Greece
Email: emlallas@gmail.com

*Celeste Lebbé, MD*
Professor of Dermatology
Department of Dermatology
Hôpital Saint-Louis
1, Avenue Claude-Vellefaux
Paris, France
Email: celeste.lebbe@aphp.fr

**Ulrike Leiter, MD**
Professor of Dermatology
Department of Dermatology
Eberhard Karls University
Liebermeister Str. 25
Tuebingen, Germany
Email: ulrike.leiter@med.uni-tuebingen.de

**K**

*Lidija Kandolf Sekulovic, MD*
Professor of Dermatology
Department of Dermatology
Medical Faculty
Military Medical Academy
Crnotravska 17
Belgrade, Serbia
Email: lkandolfsekulovic@gmail.com
M

Josep Malvehy, MD
Director of the Melanoma Unit
Department of Dermatology
Hospital Clinic of Barcelona
C/Villarroel 170
Barcelona, Spain
Email: jmalvehy@clinic.ub.es

David Moreno-Ramirez, MD
University Hospital Virgen Macarena
Calle Dr. Fedriani, 3
Seville, Spain
Email: dmoreno@e-derma.org

O

Judit Oláh, MD
Department of Dermatology
University of Szeged
Koranyi Fasor 6
Szeged, Hungary
Email: dr.olah.judit@gmail.com

P

Ketty Peris, MD
Department of Dermatology
Catholic University of Rome
Largo a Gemelli, 8
Rome, Italy
Email: ketty.peris@rm.unicatt.it

T

Franz Trautinger, MD
University Hospital St. Pölten
Head of Dermatology
Dunant-Platz 1
St. Pölten, Austria
Email: franz.trautinger@stpoelten.lknoe.at

Z

Iris Zalaudek, MD
Head of the Dermatology Clinic
University of Trieste
Hospital Maggiore
Piazza dell’ Ospedale 1
Trieste, Italy
Email: iris.zalaudek@gmail.com
General Information

Cancellation Policy
Cancellations must be received in writing by December 18, 2020. No refunds will be granted after that date. A processing fee of 30 Euro will be deducted from each cancelled registration. Substitutions are possible. To substitute a registration, please send an email including the name of the original registrant and the name of the person substituting to info@medconcept.org.

The participant acknowledges that he/she has no right to lodge damage claims against the organizers should the holding of the meeting be hindered or prevented by unexpected, political or economic events or generally by force, or should the non-appearance of speakers or other reasons need program changes. With registration, the participant accepts this proviso.

Course Organization

MEDCONCEPT

MedConcept Gesellschaft für medizinische Projekte mbH
Friedenstraße 58
15366 Neuenhagen b. Berlin, Germany
Phone: +49 (0)3342 42689-30
Fax: +49 (0)3342 42689-40
E-Mail: info@medconcept.org
www.medconcept.org

Fee
Registration Fee of **120 Euro (incl. VAT)**

Language and Translation
The official language of the meeting will be English. Simultaneous translation will not be provided.
GOLD SPONSOR

Bristol Myers Squibb

NOVARTIS

BRONZE SPONSORS

Pierre Fabre

FURTHER SPONSORS

almirall

MSD

SUN PHARMA
TOPICS:
Actinic keratosis • Basal cell carcinoma
Cutaneous sarcoma • Cutaneous T- and B-cell lymphoma
Melanoma • Merkel cell carcinoma • Rare tumors
Squamous cell carcinoma

Prof. Paolo Ascierto  
Naples, Italy

Prof. Claus Garbe  
Tuebingen, Germany

Prof. Axel Hauschild  
Kiel, Germany

Prof. Ketty Peris  
Rome, Italy

Prof. Mario Santinami  
Milan, Italy
Save the Date
July 8th–9th, 2021
Munich, Germany
Hilton Hotel Munich Park

www.postchicago2021.org

11th European Post-Chicago Melanoma/Skin Cancer Meeting

Congress Presidents
Axel Hauschild, Kiel, Germany
Claus Garbe, Tuebingen, Germany